Deutsch English Français

Contact

EP2380592

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2380592

EP2380592 - Antagonist antibody directed against calcitonin gene-related peptide [Right-click to bookmark this link]
Former [2011/43]	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
	[2017/50]
Status	No opposition filed within time limit Status updated on 11.01.2019 Database last updated on 23.04.2024
Former	The patent has been granted Status updated on 02.02.2018
Former	Grant of patent is intended Status updated on 30.11.2017
Former	Examination is in progress Status updated on 23.12.2016
Most recent event Tooltip	11.01.2019	No opposition filed within time limit	published on 13.02.2019 [2019/07]
Applicant(s)	For all designated states Teva Pharmaceuticals International GmbH Schlüsselstrasse 12 8645 Jona / CH
	[2017/30]
Former [2013/08]	For all designated states Labrys Biologics Inc. 1700 Owens Street No. 595 San Francisco, CA 94158 / US
Former [2011/43]	For all designated states Rinat Neuroscience Corp. 230 East Grand Avenue South San Francisco, CA 94080 / US
Inventor(s)	01 / Zeller, Joerg Rinat Neuroscience Corp. 230 East Grand Avenue South San Francisco, CA 94080 / US
	02 / Poulsen, Kristian, Todd Rinat Neuroscience, Corp. 230 East Grand Avenue South San Francisco, CA 94080 / US
	03 / Abdiche, Yasmina, Noubia Rinat Neuroscience Corp. 230 East Grand Avenue South San Francisco, CA 94080 / US
	04 / Pons, Jaume Rinat Neuroscience, Corp. 230 East Grand Avenue South San Francisco, CA 94080 / US
	05 / Rosenthal, Arnon 150 Normandy Lane Woodside, CA 94062 / US
	06 / Collier, Sierra, Jones Rinat Neuroscience, Corp. 230 East Grand Avenue South San Francisco, CA 94080 / US
	[2011/43]
Representative(s)	Marshall, Cameron John, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[2018/10]
Former [2013/08]	Roques, Sarah Elizabeth J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
Former [2012/33]	Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
Former [2011/43]	Porter, Jonathan Philip Pfizer European Patent Department 23-25, avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
Application number, filing date	11166787.9	02.11.2006
	[2011/43]
Priority number, date	US20050736623P	14.11.2005 Original published format: US 736623 P
	[2011/43]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP2380592
	Date:	26.10.2011
	Language:	EN
	[2011/43]
	Type:	A3 Search report
	No.:	EP2380592
	Date:	06.06.2012
	Language:	EN
	[2012/23]
	Type:	B1 Patent specification
	No.:	EP2380592
	Date:	07.03.2018
	Language:	EN
	[2018/10]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	08.05.2012
Classification	IPC:	A61K39/395, A61P5/24, C07K16/26	[2012/23]
	CPC:	A61K31/4045 (EP,US); C07K16/18 (NO,US); A61K39/395 (KR,NO); A61K39/3955 (EP,US); A61P25/00 (EP); A61P25/06 (EP); (+) A61P29/00 (EP); A61P43/00 (EP); A61P5/00 (EP); A61P5/24 (EP); A61P9/00 (EP); C07K16/00 (KR); C07K16/26 (EP,US); A61K2039/505 (EP,US); C07K2317/21 (US); C07K2317/24 (US); C07K2317/33 (EP,US); C07K2317/34 (EP,US); C07K2317/52 (US); C07K2317/55 (EP,US); C07K2317/56 (US); C07K2317/565 (EP,US); C07K2317/567 (US); C07K2317/70 (EP,US); C07K2317/71 (US); C07K2317/76 (EP,US); C07K2317/92 (EP,US); C07K2317/94 (US) (-)
	Former IPC [2011/43]	A61K39/395, C07K14/585, A61P25/00, C07K16/26
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2018/10]
Former [2011/43]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
Extension states	AL	06.12.2012
	BA	06.12.2012
	HR	06.12.2012
	MK	06.12.2012
	RS	06.12.2012
Title	German:	Antagonist-Antikörper gegen calcitonin-Gen-related-Peptid	[2017/50]
	English:	Antagonist antibody directed against calcitonin gene-related peptide	[2017/50]
	French:	Anticorps antagoniste orienté contre un peptide lié au gène de la calcitonine	[2017/50]
	Former [2011/43]	Antagonisten-Antikörper gegen calcitonin-Gen-related-Peptid und Verfahren damit
	Former [2011/43]	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
	Former [2011/43]	Anticorps antagonistes orientés contre un peptide lié au gène de la calcitonine, et procédés d'utilisation correspondants
Biological material	This application mentions deposited biological material, check the file for details
Examination procedure	06.12.2012	Amendment by applicant (claims and/or description)
	06.12.2012	Examination requested [2013/03]
	20.07.2015	Despatch of a communication from the examining division (Time limit: M06)
	24.02.2016	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	05.05.2016	Reply to a communication from the examining division
	17.08.2016	Despatch of a communication from the examining division (Time limit: M06)
	23.01.2017	Reply to a communication from the examining division
	06.11.2017	Cancellation of oral proceeding that was planned for 13.11.2017
	13.11.2017	Date of oral proceedings (cancelled)
	01.12.2017	Communication of intention to grant the patent
	22.01.2018	Fee for grant paid
	22.01.2018	Fee for publishing/printing paid
	22.01.2018	Receipt of the translation of the claim(s)
Parent application(s) Tooltip	EP06809207.1 / EP1957106
Divisional application(s)	EP16154411.9 / EP3069731
	EP16154418.4 / EP3045182
	EP17152503.3 / EP3178493
	EP20200867.8
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060809207) is 20.05.2009
Opposition(s)	10.12.2018	No opposition filed within time limit [2019/07]
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	05.05.2016	Request for further processing filed
	05.05.2016	Full payment received (date of receipt of payment) Request granted
	18.05.2016	Decision despatched
Fees paid	Renewal fee
	19.09.2011	Renewal fee patent year 03
	19.09.2011	Renewal fee patent year 04
	19.09.2011	Renewal fee patent year 05
	07.11.2011	Renewal fee patent year 06
	07.11.2012	Renewal fee patent year 07
	18.11.2013	Renewal fee patent year 08
	25.11.2014	Renewal fee patent year 09
	24.11.2015	Renewal fee patent year 10
	23.11.2016	Renewal fee patent year 11
	24.11.2017	Renewal fee patent year 12
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]US2005234054 (MUELLER STEPHAN G [DE], et al) [Y] 1-13 * paragraphs [0065] , [0066] *;
		[Y] - FROBERT Y ET AL, "A sensitive sandwich enzyme immunoassay for calcitonin gene-related peptide (CGRP): characterization and application.", PEPTIDES 1999, (1999), vol. 20, no. 2, ISSN 0196-9781, pages 275 - 284, XP002430636 [Y] 1-13 * the whole document * DOI: http://dx.doi.org/10.1016/S0196-9781(98)00172-7
		[Y] - TAN K K ET AL, "Calcitonin gene-related peptide as an endogenous vasodilator: immunoblockade studies in vivo with an anti-calcitonin gene-related peptide monoclonal antibody and its Fab' fragment.", CLINICAL SCIENCE (LONDON, ENGLAND : 1979) DEC 1995, (199512), vol. 89, no. 6, ISSN 0143-5221, pages 565 - 573, XP009082539 [Y] 1-13 * the whole document * DOI: http://dx.doi.org/10.1042/cs0890565
		[A] - BALINT R F ET AL, "ANTIBODY ENGINEERING BY PARSIMONIOUS MUTAGENESIS", GENE, ELSEVIER, AMSTERDAM, NL, (19931227), vol. 137, no. 1, ISSN 0378-1119, pages 109 - 118, XP002031537 [A] 1-13 * page 110, column R * DOI: http://dx.doi.org/10.1016/0378-1119(93)90258-5
		[A] - LITTLE M ET AL, "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20000801), vol. 21, no. 8, ISSN 0167-5699, pages 364 - 370, XP004215163 [A] 1-13 * abstract * DOI: http://dx.doi.org/10.1016/S0167-5699(00)01668-6
		[A] - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (200311), vol. 21, no. 11, ISSN 0167-7799, pages 484 - 490, XP004467495 [A] 1-13 * abstract * DOI: http://dx.doi.org/10.1016/j.tibtech.2003.08.007
		[A] - DAVIES J ET AL, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, (199609), vol. 2, no. 3, ISSN 1380-2933, pages 169 - 179, XP004070292 [A] 1-13 * abstract * DOI: http://dx.doi.org/10.1016/S1380-2933(96)00045-0
	Examination	- TAN K K ET AL, "Demonstration of the neurotransmitter role of calcitonin gene-related peptides (CGRP) by immunoblockade with anti-CGRP monoclonal antibodies.", BRITISH JOURNAL OF PHARMACOLOGY MAR 1994, (199403), vol. 111, no. 3, ISSN 0007-1188, pages 703 - 710
		- BUCKLEY T L ET AL, "THE PARTIAL INHINITION OF INFLAMMATORY RESPONSES INDUCED BY CAPSAICIN USING THE FAB FRAGMENT OF A SELECTIVE CALCITONIN GENE-RELATED PEPTIDE ANTISERUM IN RABBIT SKIN", NEUROSCIENCE, NEW YORK, NY, US, (19920101), vol. 48, no. 4, doi:10.1016/0306-4522(92)90284-9, ISSN 0306-4522, pages 963 - 968, XP000563679 DOI: http://dx.doi.org/10.1016/0306-4522(92)90284-9
		- Dan Hurley, "News from the American Headache Society Annual Meeting: CGRP Drug Improves Wellness on Headache-Free Days, Study Finds", Neurology Today, doi:10.1097/01.NT.0000489588.15047.0c, (20160707), pages 31 - 31, URL: http://journals.lww.com/neurotodayonline/Fulltext/2016/07070/News_from_the_American_Headache_Society_Annual.8.aspx, (20170425), XP055367323 DOI: http://dx.doi.org/10.1097/01.NT.0000489588.15047.0c
		- WONG H C ET AL, "MONOCLONAL ANTIBODY TO RAT ALPHA-CGRP: PRODUCTION, CHARACTERIZATION, AND IN VIVO IMMUNONEUTRALIZATION ACTIVITY", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, (19930101), vol. 12, no. 1, ISSN 0272-457X, pages 93 - 106, XP009082532
		- PESKAR B M ET AL, "A monoclonal antibody to calcitonin gene-related peptide abolishes capsaicin-induced gastroprotection", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 250, no. 1, doi:10.1016/0014-2999(93)90645-X, ISSN 0014-2999, (19931130), pages 201 - 203, (19931130), XP025569068 DOI: http://dx.doi.org/10.1016/0014-2999(93)90645-X
		- Max Reinshagen ET AL, "Calcitonin Gene-Related Peptide Mediates the Protective Effect of Sensory Nerves in a Model of Colonic Injury 1", (19980101), URL: http://jpet.aspetjournals.org/content/jpet/286/2/657.full.pdf, (20170418), XP055365033
		- LOUIS S M ET AL, "The role of substance P and calcitonin gene-related peptide in neurogenic plasma extravasation and vasodilatation in the rat", NEUROSCIENCE, NEW YORK, NY, US, vol. 32, no. 3, doi:10.1016/0306-4522(89)90281-9, ISSN 0306-4522, (19890101), pages 581 - 586, (19890101), XP024383568 DOI: http://dx.doi.org/10.1016/0306-4522(89)90281-9
		- Bigal et al., "Safety, tolerability, and effi cacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study", neurology Articles Lancet Neurol, (20150930), pages 1091 - 100, URL: http://www.thelancet.com/pdfs/journals/laneur/PIIS1474-4422(15)00245-8.pdf, (20171018), XP055416827
		- Bigal et al., "Safety, tolerability, and effi cacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study", (20150930), URL: http://www.thelancet.com/pdfs/journals/laneur/PIIS1474-4422(15)00249-5.pdf, (20171016), XP055416829
	by applicant	US3773919
		EP0003089
		US4485045
		US4544545
		US4676980
		US4683195
		US4683202
		WO8704462
		US4754065
		GB2200651
		US4777127
		US4800159
		US4816567
		EP0345242
		WO9007936
		WO9011092
		WO9100360
		WO9102805
		US5013556
		US5047335
		WO9114445
		WO9220373
		EP0519596
		EP0524968
		WO9303769
		WO9306213
		WO9310218
		WO9311230
		US5219740
		WO9319191
		WO9325698
		WO9325234
		US5278299
		WO9403622
		WO9404690
		WO9412649
		WO9423697
		WO9428938
		WO9500655
		WO9507994
		WO9511984
		WO9513796
		US5422120
		WO9530763
		US5500362
		US5510261
		WO9617072
		US5530101
		US5545807
		US5545806
		US5565332
		US5569825
		US5580717
		US5580859
		US5585089
		US5625126
		US5633425
		US5661016
		WO9742338
		US5693761
		US5693762
		US5733743
		US5750373
		US5807715
	US5814482
	US5821337
	US5866692
	US5981568
	WO9958572
	US5997867
	US6054297
	WO0053211
	US6180370
	US6180377
	US6210671
	WO0127160
	US6265150
	US6331415
	US6350861
	US6376471
	US6413942
	US6436908
	WO2004058184
	- WYON ET AL., SCAND. J. UROL. NEPHROL., (2001), vol. 35, pages 92 - 96
	- WYON ET AL., MENOPAUSE, (2000), vol. 7, no. 1, pages 25 - 30
	- FREEDMAN, AM. J. HUMAN BIOL., (2001), vol. 13, pages 453 - 464
	- MURPHY ET AL., 3.SUP.RD INT'! SYMPOSIUM ON RECENT ADVANCES IN UROLOGICAL CANCER DIAGNOSIS AND TREATMENT-PROCEEDINGS, (1992), pages 3 - 7
	- KATOVICH ET AL., PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE, (1990), vol. 193, no. 2, pages 129 - 35
	- BERENDSEN ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, (2001), vol. 419, no. 1, pages 47 - 54
	- DURHAM, N. ENGL. J. MED., (2004), vol. 350, pages 1073 - 1075
	- GOADSBY ET AL., ANN. NEUROL., (1990), vol. 28, pages 183 - 7
	- LASSEN ET AL., CEPHALALGIA, (2002), vol. 22, pages 54 - 61
	- BRAIN, S. ET AL., TRENDS IN PHARMACOLOGICAL SCIENCES, (2002), vol. 23, pages 51 - 53
	- GOADSBY ET AL., BRAIN, (2002), vol. 125, pages 1392 - 401
	- ARULMANI ET AL., CEPHALALGIA, (2005), vol. 25, pages 1082 - 1090
	- GIFFIN ET AL., CEPHALALGIA, (2003), vol. 23, pages 287 - 292
	- ARULMANI ET AL., EUR. J. PHARMACOL., (2004), vol. 500, pages 315 - 330
	- GOADSBY ET AL., NEW ENGL. J. MED., (2002), vol. 346, no. 4, pages 257 - 275
	- GOADSBY, P.J. ET AL., NEW ENGL. J. MED., (2002), vol. 346, no. 4, pages 257 - 275
	- EUR. J. IMMUNOL., (1999), vol. 29, pages 2613 - 2624
	- Methods in Molecular Biology, HUMANA PRESS
	- Methods in Enzymology, ACADEMIC PRESS, INC.
	- Handbook of Experimental Immunology
	- KOHLER, MILSTEIN, NATURE, (1975), vol. 256, page 495
	- MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554
	- VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 309 - 314
	- SHEETS ET AL., PNAS, (1998), vol. 95, pages 6157 - 6162
	- HOOGENBOOM, WINTER, J. MOL. BIOL., (1991), vol. 227, page 381
	- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581
	- COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77
	- BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, no. 1, pages 86 - 95
	- AL-LAZIKANI ET AL., J. MOLEC. BIOL., (1997), vol. 273, pages 927 - 948
	- RAVETCH, KINET, ANN. REV. IMMUNOL., (1991), vol. 9, pages 457 - 92
	- CAPEL ET AL., IMMUNOMETHODS, (1994), vol. 4, pages 25 - 34
	- DE HAAS ET AL., J. LAB. CLIN. MED., (1995), vol. 126, pages 330 - 41
	- GUYER ET AL., J. IMMUNOL., (1976), vol. 117, page 587
	- KIM ET AL., J. IMMUNOL., (1994), vol. 24, page 249
	- GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, (1996), vol. 202, page 163
	- CLYNES ET AL., PNAS, (1998), vol. 95, pages 652 - 656
	- EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 3688
	- HWANG ET AL., PROC. NATL ACAD. SCI. USA, (1980), vol. 77, page 4030
	- GOADSBY ET AL., N. ENGL. J. MED., (2002), vol. 346, pages 257 - 270
	- TAN ET AL., CLIN. SCI., (1995), vol. 89, pages 565 - 73
	- PLOURDE ET AL., PEPTIDES, (1993), vol. 14, pages 1225 - 1229
	- EUR. J. LMMUNOL., (1999), vol. 29, pages 2613 - 2624
	- KARLSSON, R. ROOS, H. FAGERSTAM, L. PETERSSON, B., METHODS ENZYMOLOGY, (1994), vol. 6, pages 99 - 110
	- KOHLER, B., MILSTEIN, C., NATURE, (1975), vol. 256, pages 495 - 497
	- BUCK, D. W. ET AL., IN VITRO, (1982), vol. 18, pages 377 - 381
	- WINTER ET AL., NATURE, (1991), vol. 349, pages 293 - 299
	- LOBUGLIO ET AL., PROC. NAT. ACAD. SCI. USA, (1989), vol. 86, pages 4220 - 4224
	- SHAW ET AL., J IMMUNOL., (1987), vol. 138, pages 4534 - 4538
	- BROWN ET AL., CANCER RES., (1987), vol. 47, pages 3577 - 3583
	- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
	- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
	- JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
	- DAUGHERTY ET AL., NUCL. ACIDS RES., (1991), vol. 19, pages 2471 - 2476
	- WINTER ET AL., ANNU. REV. IMMUNOL., (1994), vol. 12, pages 433 - 455
	- MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 553
	- JOHNSON, KEVIN S., CHISWELL, DAVID J., CURRENT OPINION IN STRUCTURAL BIOLOGY, (1993), vol. 3, pages 564 - 571
	- CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
	- MARK ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
	- GRIFFITH ET AL., EMBO J., (1993), vol. 12, pages 725 - 734
	- MARKS ET AL., BIO/TECHNOL., (1992), vol. 10, pages 779 - 783
	- WATERHOUSE ET AL., NUCL. ACIDS RES., (1993), vol. 21, pages 2265 - 2266
	- PEETERS ET AL., VACCINE, (2001), vol. 19, page 2756
	- LONBERG, N., D. HUSZAR, LNT.REV.LMMUNOL, (1995), vol. 13, page 65
	- POLLOCK ET AL., J LMMUNAL METHODS, (1999), vol. 231, page 147
	- MORRISON ET AL., PROC. NAT. ACAD. SCI., (1984), vol. 81, page 6851
	- ESCOTT ET AL., BR. J. PHARMACOL., (1993), vol. 110, pages 772 - 776
	- REUTER ET AL., FUNCTIONAL NEUROLOGY, (2000), page 3
	- FINDEIS ET AL., TRENDS BIOTECHNOL., (1993), vol. 11, page 202
	- WU ET AL., J. BIOL. CHEM., (1988), vol. 263, page 621
	- WU ET AL., J. BIOL. CHEM., (1994), vol. 269, page 542
	- ZENKE ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, page 3655
	- WU ET AL., J. BIOL. CHEM., (1991), vol. 266, page 338
	- JOLLY, CANCER GENE THERAPY, (1994), vol. 1, page 51
	- KIMURA, HUMAN GENE THERAPY, (1994), vol. 5, page 845
	- CONNELLY, HUMAN GENE THERAPY, (1995), vol. 1, page 185
	- KAPLITT, NATURE GENETICS, (1994), vol. 6, page 148
	- CURIEL, HUM. GENE THER., (1992), vol. 3, page 147
	- WU, J. BIOL. CHEM., (1989), vol. 264, page 16985
	- PHILIP, MOL. CELL BIOL., (1994), vol. 14, page 2411
	- WOFFENDIN, PROC. NATL. ACAD. SCI., (1994), vol. 91, page 1581
	- BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
	- HOLLIGER, P. ET AL., PROC. NATL. ACAD SCI. USA, (1993), vol. 90, pages 6444 - 6448
	- POLJAK, R. J. ET AL., STRUCTURE, (1994), vol. 2, pages 1121 - 1123
	- SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210
	- MILLSTEIN, CUELLO, NATURE, (1983), vol. 305, pages 537 - 539
	- JEFFERIS, LUND, CHEM. IMMUNOL., (1997), vol. 65, pages 111 - 128
	- WRIGHT, MORRISON, TIBTECH, (1997), vol. 15, pages 26 - 32
	- BOYD ET AL., MOL. IMMUNOL., (1996), vol. 32, pages 1311 - 1318
	- WITTWE, HOWARD, BIOCHEM., (1990), vol. 29, pages 4175 - 4180
	- WYSS, WAGNER, CURRENT OPIN. BIOTECH., (1996), vol. 7, pages 409 - 416
	- UMANA ET AL., MATURE BIOTECH., (1999), vol. 17, pages 176 - 180
	- HSE ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 9062 - 9070
	- MORGAN ET AL., IMMUNOLOGY, (1995), vol. 86, pages 319 - 324
	- LUND ET AL., J. IMMUNOLOGY, (1996), vol. 157, pages 4963 - 9
	- LDUSOGIE, J. IMMUNOLOGY, (2000), vol. 164, pages 4178 - 4184
	- TAO ET AL., J. IMMUNOLOGY, (1989), vol. 143, pages 2595 - 2601
	- JEFFERIS ET AL., IMMUNOLOGICAL REVIEWS, (1998), vol. 163, pages 59 - 76
	- MARKS ET AL., BIOFTECHNOLOGY, (1992), vol. 10, pages 779 - 783
	- BARBAS ET AL., PROC NAT. ACAD. SCI, (1994), vol. 91, pages 3809 - 3813
	- SCHIER ET AL., GENE, (1995), vol. 169, pages 147 - 155
	- YELTON ET AL., J, IMMUNOL., (1995), vol. 155, pages 1994 - 2004
	- JACKSON ET AL., J. IMMUNOL., (1995), vol. 154, no. 7, pages 3310 - 9
	- HAWKINS ET AL., J. MOL. BIOL., (1992), vol. 226, pages 889 - 896
	- BALINT ET AL., GENE, (1993), vol. 137, no. 1, pages 109 - 18
	- "A model of evolutionary change in proteins - Matrices for detecting distant relationships", DAYHOFF, M.O., Atlas of Protein Sequence and Structure, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, (1978), vol. 5, pages 345 - 358
	- "Unified Approach to Alignment and Phylogenes", HEIN J., Methods in Enzymology, ACADEMIC PRESS, INC., (1990), vol. 183, pages 626 - 645
	- HIGGINS, D.G., SHARP, P.M., CABIOS, (1989), vol. 5, pages 151 - 153
	- MYERS, E.W., MULLER W., CABIOS, (1988), vol. 4, pages 11 - 17
	- ROBINSON, E.D., COMB. THEOR., (1971), vol. 11, page 105
	- SANTOU, N., NES, M., MOL. BIOL. EVOL., (1987), vol. 4, pages 406 - 425
	- WILBUR, W.J., LIPMAN, D.J., PROC. NATL. ACAD. SCI. USA, (1983), vol. 80, pages 726 - 730
	- GEERLIGS HJ ET AL., J. IMMUNOL. METHODS, (1989), vol. 124, pages 95 - 102
	- KENNEY JS ET AL., J. LMMUNOL. METHODS, (1989), vol. 121, pages 157 - 166
	- WICHER K ET AL., INT. ARCH. ALLERGY APPL, IMMUNOL., (1989), vol. 89, pages 128 - 135
	- ZIMMERMANN ET AL., PEPTIDES, (1995), vol. 16, pages 421 - 4
	- MALLEE ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 14294 - 8
	- TAN ET AL., CLIN. SCI., (1995), vol. 89, pages 656 - 73
	- BARBAS, Phage display: a laboratory manual, COLD SPRING HARBOR LABORATORY PRESS, (2001), page 2.10
	- WILLIAMSON ET AL., CEPHALALGIA, (1997), vol. 17, no. 4, pages 518 - 24
	- SIPE ET AL., BRAIN RES., (2004), vol. 1028, no. 2, pages 191 - 202
	- MERCHENTHALER ET AL., MATURITAS, (1998), vol. 30, pages 307 - 316
	- KATOVICH ET AL., BRAIN RES., (1989), vol. 494, pages 85 - 94
	- SIMPKINS ET AL., LIFE SCIENCES, (1983), vol. 32, pages 1957 - 1966
	GB19980009951
	WO1999GB01441

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p